HURA - TuHURA Biosciences, Inc. Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

HURA

TUHURA BIOSCIENCES, INC.

NASDAQ

$1.93

▼ DOWN 2.53% (-0.05)

KEY STATISTICS

Market Cap$124.18 M

52w High$3.43

52w Low$0.41

Dividend Yield—

Frequency—

P/E-3.61

Volume316.22K

Shares Out.63.68M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

James A. Bianco

ABOUT

SECTOR

Healthcare

WENT PUBLIC

February 22, 2013

METHOD OF GOING PUBLIC

N/A

FULL TIME EMPLOYEES

UPCOMING EARNINGS

DateNov 13, 2026

DayFriday

Rev. Est.—

NOV

FRI

SPLIT RECORD

DATE	TYPE	RATIO
2024-10-18	Reverse	1:35
2022-11-14	Reverse	1:50
2019-05-08	Reverse	1:10
2016-05-23	Reverse	1:4

ETFS HOLDING THIS STOCK

ETFS HOLDING

LISTED HERE

RANKED BY POSITION SIZE

INSTITUTIONAL OWNERSHIP

SHARES OWNED

11.88%

HOLDERS

TOP 8 OF 98 · RANKED BY POSITION SIZE

Geode Capital Management, LLC

986.9K sh

$1.77M

Aqr Capital Management LLC

Bank Of New York Mellon Corp

PRICE

$1.93 ▼ DOWN 2.53% (−$0.05)

OVERLAYS

About TuHURA Biosciences, Inc.

http://www.tuhurabio.com ↗

TuHURA Biosciences, Inc. is a phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company is headquartered in Tampa, FL.

INDUSTRY

Biotechnology

A PRODUCT TUHURA BIOSCIENCES, INC. IS KNOWN FOR

IFx-2.0

IFx-2.0, TuHURA Biosciences' lead Phase 3 innate immune agonist, aims to overcome resistance to checkpoint inhibitors and is being tested with Keytruda® for advanced Merkel Cell Carcinoma.

COMPETITORS

COMPETITOR

TuHURA Biosciences in 2025

SENTIMENT: + POSITIVE

REGULATORY · JUNE 2025

TuHURA Biosciences Initiates Pivotal Phase 3 Trial for Cancer Immunotherapy IFx-2.0 Under FDA Special Protocol Assessment

In a significant step towards potential commercialization, TuHURA Biosciences initiated a Phase 3 accelerated approval trial for its lead cancer immunotherapy candidate, IFx-2.0, in June 2025. The trial, conducted under a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA), is for the first-line treatment of advanced and metastatic Merkel cell carcinoma. This milestone event occurred amidst a series of major developments, including the completion of the Kineta, Inc. acquisition and securing $15.5 million in funding, collectively putting the company in the spotlight for investors and the biotech industry.

ACQUISITION · JUNE 2025 · COMPLETED

TuHURA Biosciences Acquires Kineta, Inc., Expanding Immuno-Oncology Pipeline with Novel VISTA Inhibitor

TuHURA Biosciences completed the acquisition of Kineta, Inc., a strategic move that adds a Phase 2-ready VISTA inhibiting monoclonal antibody, now named TBS-2025, to its pipeline. This acquisition diversifies TuHURA's portfolio beyond its lead candidate and marks its entry into developing treatments for blood-related cancers like Acute Myeloid Leukemia (AML).

Latest News

PRNEWSWIRE · OCT 5, 2026

TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology

Patent discloses uses beyond ADCs, including autologous or allogeneic adoptive cellular immunotherapies like CAR-T, Tregs or TIL cell therapies TAMPA, Fla., Oct. 5, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that the United States Patent and Trademark Office has issued U.S. Patent No.

READ ARTICLE